Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Why GLP-1 treatment response varies
A 2026 review finds no single baseline trait reliably predicts GLP-1 response. Early treatment response remains the clearest clinical signal.
Ipamorelin After Hives: Evidence Limits
No clinical evidence shows that ipamorelin alone is a safe substitute after hives from another peptide or that it improves sleep and recovery.
GLP-1 drugs and skin: what JAAD flagged
A new JAAD editorial puts skin changes and medicolegal questions around semaglutide and tirzepatide on the dermatology agenda.
Oral semaglutide nanomicelles in mice
A mouse study tests dual-transporter-targeted semaglutide nanomicelles. The early result is about delivery science, not a new treatment.
Regenerative Peptides for Tissue Repair
A 2026 review finds limited human evidence for many regenerative peptides used for tissue repair and chronic pain claims.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.
BPC-157 and TB-500 for Endurance Running
A recurring r/peptides question asks if the wolverine stack helps runners. No human trial has tested it, and both peptides remain unapproved drugs.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
GLP-1 drugs: eye and mood safety signals
A new pharmacovigilance study flags eye and psychiatric signals with semaglutide. Here is what it found, and what regulators already concluded.
GLP-1 Drugs and Psoriasis: Real-World Data
A JEADV cohort letter finds GLP-1 and dual GLP-1/GIP agonists associated with changes in healthcare resource use among patients with established psoriasis.
GLP-1 drugs in IIH: what research shows
A 2026 Headache meta-analysis finds GLP-1 receptor agonists reduce intracranial pressure and headache days in IIH. What the data shows.